Abstract
Myositis-specific autoantibodies (MSAs) are hallmarks of idiopathic inflammatory myopathies (IIMs) and have become increasing valuable in disease diagnosis, phenotyping, and classification. In addition to their clinical utility, emerging data, including findings from several animal studies, suggest that MSAs and autoreactive T cells substantially contribute to the aetiopathogenesis of IIMs. This review aims to provide an updated perspective on myositis autoantibodies by focusing on relevant clinical and translational studies.
| Original language | English |
|---|---|
| Pages (from-to) | 364-371 |
| Number of pages | 8 |
| Journal | Clinical and Experimental Rheumatology |
| Volume | 43 |
| Issue number | 2 |
| Early online date | 31 Oct 2024 |
| DOIs | |
| Publication status | Published - 26 Feb 2025 |
Bibliographical note
Publisher Copyright:© Copyright CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 2025.
Funding
G. Wang\u2019s work was supported by the National High Level Hospital Clinical Research Funding (2022-NHLH-CRF-YS-02), and National Natural Science Foundation of China (82372320). N.J. McHugh\u2019s work was supported by funding from CURE JM and the Bath Institute for Rheumatic Diseases.
| Funders | Funder number |
|---|---|
| Bath Institute For Rheumatic Diseases | |
| CURE Childhood Cancer Association | |
| National High Level Hospital Clinical Research Funding | 2022-NHLH-CRF-YS-02 |
| National Natural Science Foundation of China | 82372320 |
Keywords
- idiopathic inflammatory myopathies
- myositis autoantibodies
- pathogenesis
ASJC Scopus subject areas
- Rheumatology
- Immunology and Allergy
- Immunology